UK consults on value based pricing system
This article was originally published in Scrip
Executive Summary
The UK department of health today released for consultation its plans for introducing a value-based pricing system to determine how much it will pay for new medicines. The plan focuses on determining maximum prices or thresholds for medicines, which will reflect the different values that different treatments offer. The proposals also touch on the role that NICE, the National Institute for health and Clinical Excellence, will play.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.